Genomics and COVID-19 Vaccine Adverse Events
Launched by UNIVERSITY OF BRITISH COLUMBIA · Jan 25, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the possible genetic reasons why some people experience serious side effects after receiving the COVID-19 vaccine. While vaccines are generally very safe, some individuals have reported severe reactions like Guillain-Barré syndrome (a condition that affects the nervous system), blood clots (known as VITT/TTS), and inflammation of the heart (myocarditis/pericarditis) after vaccination. The researchers want to find out if certain genes may increase the risk of these adverse events.
To take part in this study, participants must be between the ages of 18 and 65 and have received a COVID-19 vaccine. They will be divided into two groups: those who have experienced one of the serious side effects and those who have not. Participants can expect to provide samples for genetic testing and answer some questions about their health. This research could help us understand why some people are more affected than others and improve vaccine safety for everyone.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Case: Any patient who received COVID-19 vaccines and developed GBS, VITT/TTS, or myocarditis/pericarditis after vaccination
- • Control: Any participant who received COVID-19 vaccines and does not experience GBS, VITT/TTS, or myocarditis/pericarditis.
- Exclusion Criteria:
- • Individuals who have not received a COVID-19 vaccine
- • Individuals who are unable to provide informed consent
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Bruce Carleton, PharmD
Principal Investigator
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials